The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses identifying subgroups of patients for targeted therapies in HCC
Published: 21 January 2017
Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, elaborates ...
Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, explains ...
Ricky Newton on how COA has helped practices keep their in-office dispensing in network
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, considers ...
Ted Okon, MBA, regarding the key issues faced by community oncologists today
Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses the key issues faced by community oncologists today
Ted Okon, MBA, on what COA is doing to help community oncology practices
Ted Okon, MBA, Executive Director, Community Oncology Alliance, elaborates on what COA is doing to help community oncology practices
Ted Okon, MBA, considers what can be done to encourage PBM transparency
Ted Okon, MBA, Executive Director, Community Oncology Alliance, tells us what can be done to encourage transparency at PBMs
Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM
Nate Brown, Senior Product Marketing Manager, Flatiron Health, on whether practices already in a MIPS track should consider moving to ...
Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, speculates on what might influence the adoption of biosimilars by oncologists
Mark Fendrick, MD, considers the challenges associated with value-based insurance design
Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, discusses the challenges associated with value-based insurance design when applied to ...
Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care
Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, discusses cancer patient advocacy and the ...
